美国 · SEC FORM 4
GRAIL, Inc.
GRAL · Nasdaq · CIK 0001699031 · Healthcare · Diagnostics & Research
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
35 同一窗口内观察到的 Form 4 交易行
22 sales · 13 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-10-09 · DING CHUN R.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 8,009,746
- 上期报告
- 8,565,314
- 日均成交量
- 1,933,327
- 回补天数
- 4.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-10-09 | DING CHUN R | 买入 (P) | Common Stock | 16,200 | USD 12.92 | USD 209,304 | SEC 申报 ↗ |
| 2024-10-03 | DING CHUN R | 买入 (P) | Common Stock | 35,000 | USD 12.71 | USD 444,850 | SEC 申报 ↗ |
| 2024-10-02 | DING CHUN R | 买入 (P) | Common Stock | 20,000 | USD 13.37 | USD 267,400 | SEC 申报 ↗ |
| 2024-10-01 | DING CHUN R | 买入 (P) | Common Stock | 7,629 | USD 13.52 | USD 103,144 | SEC 申报 ↗ |
Form 4 申报证据
69 transaction lines in the latest 365-day window; 142 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | SUMME GREGORY L | 奖励／授予 (A) | Common Stock | 237 | USD 135.46 | USD 32,104 | SEC 申报 ↗ |
| 2026-10-15 | Ofman Joshua J. | 卖出 (S) | Common Stock | 20,000 | USD 136.85 | USD 2,736,945 | SEC 申报 ↗ |
| 2026-10-15 | MIZELL STEVEN | 奖励／授予 (A) | Common Stock | 148 | USD 135.46 | USD 20,048 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | SUMME GREGORY L | 奖励／授予 (A) | Common Stock | 237 | USD 135.46 | USD 32,104 | SEC 申报 ↗ |
| 2026-10-15 | Ofman Joshua J. | 卖出 (S) | Common Stock | 20,000 | USD 136.85 | USD 2,736,945 | SEC 申报 ↗ |
| 2026-10-15 | MIZELL STEVEN | 奖励／授予 (A) | Common Stock | 148 | USD 135.46 | USD 20,048 | SEC 申报 ↗ |
| 2026-10-15 | CHASE WILLIAM J | 奖励／授予 (A) | Common Stock | 153 | USD 135.46 | USD 20,725 | SEC 申报 ↗ |
| 2026-10-05 | Partridge Andrew John | 卖出 (S) | Common Stock | 7,873 | USD 146.39 | USD 1,152,528 | SEC 申报 ↗ |
| 2026-10-05 | Freidin Aaron | 卖出 (S) | Common Stock | 23,619 | USD 146.39 | USD 3,457,585 | SEC 申报 ↗ |
| 2026-09-21 | Ofman Joshua J. | 卖出 (S) | Common Stock | 61,452 | USD 97.74 | USD 6,006,281 | SEC 申报 ↗ |
| 2026-09-21 | Ofman Joshua J. | 期权行权／转换 (M) | Common Stock | 26,452 | USD 14.00 | USD 370,328 | SEC 申报 ↗ |
| 2026-09-21 | Freidin Aaron | 卖出 (S) | Common Stock | 4,100 | USD 93.34 | USD 382,682 | SEC 申报 ↗ |
| 2026-08-27 | Ofman Joshua J. | 卖出 (S) | Common Stock | 5,000 | USD 85.02 | USD 425,100 | SEC 申报 ↗ |
| 2026-08-27 | Freidin Aaron | 卖出 (S) | Common Stock | 7,900 | USD 85.01 | USD 671,579 | SEC 申报 ↗ |
| 2026-07-15 | SUMME GREGORY L | 奖励／授予 (A) | Common Stock | 427 | USD 74.36 | USD 31,752 | SEC 申报 ↗ |
| 2026-07-15 | MIZELL STEVEN | 奖励／授予 (A) | Common Stock | 268 | USD 74.36 | USD 19,928 | SEC 申报 ↗ |
| 2026-07-15 | CHASE WILLIAM J | 奖励／授予 (A) | Common Stock | 276 | USD 74.36 | USD 20,523 | SEC 申报 ↗ |
| 2026-06-18 | SUMME GREGORY L | 奖励／授予 (A) | Common Stock | 5,491 | USD 63.74 | USD 349,996 | SEC 申报 ↗ |
| 2026-06-18 | MIZELL STEVEN | 奖励／授予 (A) | Common Stock | 5,491 | USD 63.74 | USD 349,996 | SEC 申报 ↗ |
| 2026-06-18 | Krevans Sarah | 奖励／授予 (A) | Common Stock | 5,491 | USD 63.74 | USD 349,996 | SEC 申报 ↗ |
| 2026-06-18 | CHASE WILLIAM J | 奖励／授予 (A) | Common Stock | 5,491 | USD 63.74 | USD 349,996 | SEC 申报 ↗ |
| 2026-06-04 | Partridge Andrew John | 卖出 (S) | Common Stock | 1,491 | USD 61.08 | USD 91,070 | SEC 申报 ↗ |
| 2026-06-03 | Ofman Joshua J. | 奖励／授予 (A) | Common Stock | 3,154 | USD 61.13 | USD 192,804 | SEC 申报 ↗ |
| 2026-06-01 | Ofman Joshua J. | 奖励／授予 (A) | Common Stock | 27,901 | USD 64.40 | USD 1,796,824 | SEC 申报 ↗ |
| 2026-04-15 | SUMME GREGORY L | 奖励／授予 (A) | Common Stock | 631 | USD 49.79 | USD 31,417 | SEC 申报 ↗ |
| 2026-04-15 | MIZELL STEVEN | 奖励／授予 (A) | Common Stock | 396 | USD 49.79 | USD 19,717 | SEC 申报 ↗ |
| 2026-04-15 | CHASE WILLIAM J | 奖励／授予 (A) | Common Stock | 408 | USD 49.79 | USD 20,314 | SEC 申报 ↗ |
| 2026-04-08 | RAGUSA ROBERT P | 卖出 (S) | Common Stock | 123,502 | USD 49.92 | USD 6,165,220 | SEC 申报 ↗ |
| 2026-04-08 | Ofman Joshua J. | 卖出 (S) | Common Stock | 61,665 | USD 49.92 | USD 3,078,317 | SEC 申报 ↗ |
| 2026-04-08 | Freidin Aaron | 卖出 (S) | Common Stock | 45,806 | USD 49.92 | USD 2,286,636 | SEC 申报 ↗ |
| 2026-03-09 | RAGUSA ROBERT P | 卖出 (S) | Common Stock | 7,461 | USD 47.89 | USD 357,296 | SEC 申报 ↗ |
| 2026-03-09 | Ofman Joshua J. | 卖出 (S) | Common Stock | 2,937 | USD 47.89 | USD 140,650 | SEC 申报 ↗ |
| 2026-03-09 | Freidin Aaron | 卖出 (S) | Common Stock | 2,492 | USD 47.89 | USD 119,340 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | GRAL |
| CIK | 0001699031 |
| 行业 | Healthcare |
| 细分行业 | Diagnostics & Research Yahoo Finance |
| SEC SIC | 8071 Services-Medical Laboratories |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 142 transaction lines from 2024-06-24 to 2026-10-15 4 P purchase lines · 77 S sale lines · 61 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.